Breast Imaging

CEM, DBT show promise for preoperative breast cancer staging
By Amerigo Allegretto
Contrast-enhanced mammography and DBT could serve as alternatives to MRI for preoperative staging of breast cancer.
August 25, 2025
Contrast Injector 400
AI shows promise as second reader in breast cancer screening
By Amerigo Allegretto
AI holds potential as a second reader in double reading settings for breast cancer screening, new research shows.
August 14, 2025
Cancer Cell
Limited access to PCPs thwarts mammography screening uptake
By Kate Madden Yee
Limited access to primary care providers (PCPs) and variable screening recommendations hinder mammography uptake, researchers report.
August 1, 2025
Breast Screening Mammo
Mayo Clinic highlights radiopharmaceutical for breast cancer treatment
By AuntMinnie.com staff writers
The Mayo Clinic has treated the first breast cancer patient with a novel radiopharmaceutical therapy in a multisite clinical trial.
August 1, 2025
Breast Cancer 3 D 400
Southern Nev. imager enhances mammograms with TC score
By AuntMinnie.com staff writers
MagView platform integrates Tyrer-Cuzick (TC) risk model.
July 22, 2025
Mammogram Dense Breasts
Capitol Radiology initiates Chapter 11
By AuntMinnie.com staff writers
Maryland-based imager faced MQSA sanctions after a U.S. Food and Drug Administration (FDA) facility inspection.
July 18, 2025
Bankruptcy Petition Minerva Studio
Clairity deploys AI for breast cancer risk prediction
By Erik L. Ridley
Clairity believes that its new AI software can deliver improvements over traditional breast cancer risk-prediction models.
June 6, 2025
Clinical workflow with Clairity Breast. Graphic courtesy of Clairity.
Mobile mammography units face diagnostic challenges
By AuntMinnie.com staff writers
There are opportunities to improve the service provided by mobile mammography units, according to research presented at ASCO 2025 in Chicago.
June 1, 2025
Pxl 20250531 175048475~2
RamSoft to integrate Therapixel's MammoScreen
By AuntMinnie.com staff writers
Commercial partnership adds AI-based breast cancer screening software to RamSoft's platforms.
May 21, 2025
Business Partner Handshake Intelligence
ARRS: Get involved with breast health advocacy
By Amerigo Allegretto
At ARRS 2025, Amy Patel, MD, discussed the need for advocacy to drive legislation on insurance coverage for women with dense breasts.
May 2, 2025
In her ARRS 2025 presentation, Amy Patel, MD, discussed ways that radiologists can be proactive in influencing legislation that addresses breast density. These include working with elected officials and joining medical societies, among others.
ARRS: Most women under 40 have no imaging before breast cancer diagnosis
By Amerigo Allegretto
Most young women who are diagnosed with breast cancer had no prior imaging performed.
May 1, 2025
At ARRS 2025, Dana Kong from Case Western Reserve University presented on breast cancer trends among women aged 40 years and younger. Among her team's findings, young women who had imaging prior to their cancer diagnosis had higher receptor status and underwent surgery more frequently than those with no prior imaging.
Preop MRI fails to deliver results for breast cancer subtype
Preoperative MRI didn't improve outcomes in women with HER2-positive and hormone receptor-negative breast cancer in a new study.
April 29, 2025
Images show a palpable mass in the left breast in a 55-year-old woman. (A) Mammography shows a 26-mm ill-defined mass with fine linear calcifications in the central portion of the left breast (arrows). (B) ultrasound shows a 23-mm hypoechoic mass with calcifications in the corresponding area accompanying palpability (between the arrows). (C) An axial, fat-saturated, contrast-enhanced T1-weighted MRI scan shows an 18-mm irregular heterogeneous enhancing mass in the left breast (arrows). After breast-conserving surgery, the final pathologic report confirmed a grade II estrogen receptor–negative, progesterone receptor–negative, human epidermal growth factor receptor 2–positive invasive ductal carcinoma. There was no lymphovascular invasion, and the resection margins were clear. The patient declined both adjuvant chemotherapy and radiation therapy due to psychologic distress. (D) 11 months later, surveillance ultrasound helped to detect a new 25-mm irregular hypoechoic mass at the 12-o’clock position in the left breast (arrows). A subsequent ultrasound-guided biopsy confirmed it as a recurrence of grade II invasive ductal carcinoma, maintaining the same receptor statuses. Images courtesy of the RSNA.
Page 1 of 87
Next Page